1-(5-methyl-benzo[b]thien-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(5-methyl-benzo[b]thien-2-yl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone
• 英文别名: 3-(1-Benzylpiperidin-4-yl)-1-(5-methyl-1-benzothiophen-2-yl)propan-1-one
• 化学式: C₂₄H₂₇NOS
• 分子量: 377.55
• InChiKey: UVLMNLAFDWANMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  48.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Heteroaryl amines as novel acetylcholinesterase inhibitors
  申请人：——

  公开号：US20020049210A1

  公开（公告）日：2002-04-25

  Compounds of the formula 1 wherein ring A, ring B, ring D, R 2 , R 3 , R 4 , R 5 , R 6 ,R 11 , R 12 , R 13 , E, G, X and P are as defined below. The compounds of formula I are cholinesterase inhibitors and are useful in enhancing memory in patients suffering from dementia and Alzheimer's disease.

  化合物的公式为1，其中环A、环B、环D、R2、R3、R4、R5、R6、R11、R12、R13、E、G、X和P的定义如下。式I的化合物是胆碱酯酶抑制剂，对于患有痴呆症和阿尔茨海默病的患者增强记忆力具有有用的作用。
• Modulators of CDC2-like kinases (CLKS) and methods of use thereof
  申请人：Milne Jill

  公开号：US20070248590A1

  公开（公告）日：2007-10-25

  Provided herein are methods for using Cdc2-like kinase (Clk) modulators for treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, ocular disorders, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a Clk modulating compound in combination with another therapeutic agent.

  本文提供了使用Cdc2-like kinase (Clk)调节剂治疗和/或预防各种疾病和障碍的方法，包括与衰老或压力有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝结障碍、炎症、癌症、眼部疾病和/或潮红，以及需要增加线粒体活动的疾病或障碍。此外，提供了包含Clk调节化合物与另一种治疗剂联合使用的组合物。
• SIRTUIN MODULATING COMPOUNDS
  申请人：Nunes Joseph J.

  公开号：US20120197013A1

  公开（公告）日：2012-08-02

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新颖的调节沉默信息调节因子（sirtuin）的化合物及其使用方法。这些调节sirtuin的化合物可用于延长细胞寿命，并用于治疗和/或预防多种疾病和障碍，包括与衰老或应激有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝结障碍、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或障碍。还提供了包含sirtuin调节化合物与另一种治疗药物组合的组合物。
• Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors
  申请人：Pfizer Products Inc.

  公开号：EP1201268A2

  公开（公告）日：2002-05-02

  The present invention relates to a method of treating dementia or cognitive deficits associated with Alzheimer's Disease or Parkinson's Disease in a mammal, including a human, by administering to the mammal a D4 dopamine receptor antagonist in combination with an acetylcholine esterase inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 dopamine receptor antagonist and an acetylcholine esterase inhibitor.

  本发明涉及一种治疗与阿尔茨海默病或帕金森病相关的哺乳动物（包括人类）痴呆症或认知缺陷的方法，其方法是向哺乳动物施用 D4 多巴胺受体拮抗剂与乙酰胆碱酯酶抑制剂。它还涉及含有药学上可接受的载体、D4多巴胺受体拮抗剂和乙酰胆碱酯酶抑制剂的药物组合物。
• Pharmaceutical combinations comprising neuronal nitric oxide synthase inhibitors for the treatment of neurodegenerative diseases
  申请人：Pfizer Products Inc.

  公开号：EP1284141A2

  公开（公告）日：2003-02-19

  This invention relates to methods of treating neurodegenerative diseases, comprising administering to a patient in need of such treatment an N-NOS inhibitor in combination with either: (a) NMDA receptor antagonist; (b) a sodium channel antagonist; (c) an acetylcholine esterase inhibitor; (d) a dopamine agonist; (e) a potassium channel opener; (f) an AMPA/kainate receptor antagonist; (g) a calcium channel antagonist; (h) a GABA-A receptor modulator (e.g., a GABA-A receptor agonist); (i) TPA (j) matrix-metalloprotease inhibitor or (k) L-Dopa. The pharmaceutical compounds are also disclosed.

  本发明涉及治疗神经退行性疾病的方法，包括向需要此类治疗的患者施用 N-NOS 抑制剂与以下任一种药物的组合：(a) NMDA 受体拮抗剂；(b) 钠通道拮抗剂；(c) 乙酰胆碱酯酶抑制剂；(d) 多巴胺激动剂；(e) 钾通道开启剂；(f) AMPA/kainate 受体拮抗剂；(g) 钙通道拮抗剂；(h) GABA-A 受体调节剂（例如g.,(i) TPA (j) 基质金属蛋白酶抑制剂或 (k) 左旋多巴。还公开了药物化合物。